Vaxart, Inc. Form 8-K (June 25, 2020)

Summary

Form 8-K Item 8.01, Other Events, filed by Vaxart, Inc. for an event dated June 25, 2020. The report states that the company confirms the completed study under the research collaboration agreement with Janssen Vaccines & Prevention B.V. on the Janssen universal influenza vaccine program, with a report being compiled for Janssen. It also states that on June 25, 2020 and June 26, 2020 the company issued press releases about a Memorandum of Understanding with Attwill Medical Solutions Sterilflow, LP and the selection of its COVID-19 vaccine for the U.S. Government's Operation Warp Speed, attached as Exhibits 99.1 and 99.2. Andrei Floroiu signed June 30, 2020.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Full text

vxrt20200628_8k.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 25 , 2020

Vaxart, Inc.

(Exact name of registrant as specified in its charter)

Delaware | 001-35285 | 59-1212264
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.)
385 Oyster Point Boulevard, Suite 9A, South San Francisco, California | 94080
(Address of principal executive offices) | (Zip Code)

Registrant’s telephone number, including area code: (650) 550-3500

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class | Trading symbol | Name of each exchange on which registered
Common stock, $0.0001 par value | VXRT | The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging Growth Company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

Vaxart, Inc. (the “Company”) previously announced that it entered into a research collaboration agreement with Janssen Vaccines & Prevention B.V. (“Janssen”) to evaluate the Company’s proprietary oral vaccine platform for the Janssen universal influenza vaccine program, and that results were expected in the first half of 2020. Consistent with such expectations, the Company confirms that the study has been completed and that a report is being compiled for Janssen.

In addition, on June 25, 2020 and June 26, 2020, the Company issued press releases relating to its signing of a Memorandum of Understanding with Attwill Medical Solutions Sterilflow, LP (AMS), and the selection of its COVID-19 vaccine for the U.S. Government’s Operation Warp Speed. A copy of each press release is filed as Exhibit 99.1 and 99.2 hereto and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number | Description
99.1 | Press Release dated June 25, 2020 .
99.2 | Press Release dated June 26, 2020 .

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Vaxart, Inc.
Dated: June 30, 2020
By: | /s/ Andrei Floroiu
Andrei Floroiu
Chief Executive Officer

File and source

File

SEC_VXRT_8-K_filed2020-06-30_0001437749-20-014248.htm

Size

29,870 bytes

SHA-256

918f374e0faa5d78b9a9135a4fe5cf749fe3a77b99159cfd41c3de08c99542e4

Our copy

SEC_VXRT_8-K_filed2020-06-30_0001437749-20-014248.htm

Original

www.sec.gov